FDA risk communication strategy
This article was originally published in The Tan Sheet
Executive SummaryThe Risk Communication Advisory Committee discusses the agency's draft risk communication strategic plan and offers further advice on strategic priorities for research on effective risk communication in a meeting scheduled for April 30 and May 1. Presentations from the public are scheduled between 1 p.m. and 2 p.m. the first day and 10:30 a.m. to 11:30 a.m. the next day during the meeting at an FDA facility in Rockville, Md., according to a March 5 Federal Register notice. At its previous meeting, the committee emphasized that FDA should assess its communications to ensure safe and effective use of medical products (1"The Tan Sheet" Sept. 1, 2008, p. 8)
You may also be interested in...
Grail announced it will enroll about 6,200 people in an interventional, multi-center study evaluating its multi-cancer early-detection blood test. This is the first time health care providers will use this test to help guide patient care.
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.